Science Daily

Slow-binding inhibition of cholinesterases: Pharmacological, toxicological relevance

Researchers describe slow-binding inhibition of cholinesterases and present their pharmacological advantages over classical reversible inhibitors (e.g. long target-residence times, resulting in ...
Seeking Alpha

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica ...

Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...
Newswire

Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell ...

TORONTO, Jan. 27, 2026 /CNW/ - Eli Lilly Canada, Inc announced today that Jaypirca ® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available for use as monotherapy for the treatment of ...